Literature DB >> 18281925

Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses.

Harlan P Jones1, Yi-Chong Wang, Beau Aldridge, Jay M Weiss.   

Abstract

In vitro measures of immune responsiveness toward tumors provide relevant information regarding the prevention and metastatic potential of cancer. In addition, the compartmentalization of immune responses is likely to be an important factor in dictating host antitumor immune responses. We have previously demonstrated that injection of antibody against B cells diminished pulmonary antitumor defenses. In the current study, we determined the effect of B cells on antitumor cellular responses against a lung metastatic tumor, MADB106. Lung B cells displayed sustained surface expression of CD80 and CD86, as compared to spleen B cells, in the presence of MADB106 tumor. Removal of B cells from lung lymphocyte cultures resulted in diminished IFN-gamma secretion and tumor lysis, whereas removal of B cells from spleen lymphocytes exposed to tumor resulted in elevated IFN-gamma and increased tumor lysis. Furthermore, a correlative increase in CD80 and CD86 co-stimulatory molecule expression by lung B cells was observed in mice subjected to MADB106 tumor. These findings provide additional evidence of the importance of pulmonary B cell responses in tumor defenses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281925      PMCID: PMC2935774     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  33 in total

1.  Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma.

Authors:  Susmit Suvas; Vinod Singh; Sudhir Sahdev; Harpreet Vohra; Javed N Agrewala
Journal:  J Biol Chem       Date:  2001-11-28       Impact factor: 5.157

2.  The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation.

Authors:  H P Jones; L M Hodge; K Fujihashi; H Kiyono; J R McGhee; J W Simecka
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

Review 3.  Clinical utilization of chemokines to combat cancer: the double-edged sword.

Authors:  Chiara Dell'Agnola; Arya Biragyn
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

4.  Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.

Authors:  Y Hayakawa; K Takeda; H Yagita; S Kakuta; Y Iwakura; L Van Kaer; I Saiki; K Okumura
Journal:  Eur J Immunol       Date:  2001-06       Impact factor: 5.532

5.  Blood level of B and CD4+ lymphocytes measured before induction of an experimental tumor in rats predicts tumor progression and survival.

Authors:  M K Demetrikopoulos; R H Goldfarb; Z B Zhang; J M Weiss
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-06       Impact factor: 4.254

6.  A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo.

Authors:  Janice M Kelly; Kazuyoshi Takeda; Phillip K Darcy; Hideo Yagita; Mark J Smyth
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

7.  IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide.

Authors:  Yoshihiro Hayakawa; Kazuyoshi Takeda; Hideo Yagita; Mark J Smyth; Luc Van Kaer; Ko Okumura; Ikuo Saiki
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

8.  Differential involvement of CD40, CD80, and major histocompatibility complex class I molecules in cytotoxicity induction and interferon-gamma production by human natural killer effectors.

Authors:  Giuseppe Terrazzano; Delia Zanzi; Carmen Palomba; Ennio Carbone; Serena Grimaldi; Simona Pisanti; Silvia Fontana; Serafino Zappacosta; Giuseppina Ruggiero
Journal:  J Leukoc Biol       Date:  2002-08       Impact factor: 4.962

9.  Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

Authors:  Shin-ichiro Fujii; Kanako Shimizu; Mitchell Kronenberg; Ralph M Steinman
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

Review 10.  Immunologic mechanisms of antitumor activity.

Authors:  Francine M Foss
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

View more
  7 in total

Review 1.  Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer.

Authors:  Si-Si Wang; Wei Liu; Dalam Ly; Hao Xu; Limei Qu; Li Zhang
Journal:  Cell Mol Immunol       Date:  2018-04-08       Impact factor: 11.530

Review 2.  Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer.

Authors:  Geetha Shanmugam; Sumana Das; Sambuddha Paul; Sudeshna Rakshit; Koustav Sarkar
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

3.  Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.

Authors:  Peng Song; Wenbin Li; Xiaoxuan Wu; Zhirong Qian; Jianming Ying; Shugeng Gao; Jie He
Journal:  Cancer Immunol Immunother       Date:  2022-02-13       Impact factor: 6.630

4.  Enrichment of Tumor-Infiltrating B Cells in Group 4 Medulloblastoma in Children.

Authors:  Kuo-Sheng Wu; Ting-Yan Jian; Shian-Ying Sung; Chia-Ling Hsieh; Man-Hsu Huang; Chia-Lang Fang; Tai-Tong Wong; Yu-Ling Lin
Journal:  Int J Mol Sci       Date:  2022-05-09       Impact factor: 6.208

5.  A role for B cells in facilitating defense against an NK cell-sensitive lung metastatic tumor is revealed by stress.

Authors:  Harlan P Jones; Beau Aldridge; Katherine Boss-Williams; Jay M Weiss
Journal:  J Neuroimmunol       Date:  2017-11-03       Impact factor: 3.478

Review 6.  B cell regulation in cancer and anti-tumor immunity.

Authors:  Anushruti Sarvaria; J Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2017-06-19       Impact factor: 11.530

7.  Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.

Authors:  Linzhi Han; Hongjie Shi; Yuan Luo; Wenjie Sun; Shuying Li; Nannan Zhang; Xueping Jiang; Yan Gong; Conghua Xie
Journal:  Cancer Med       Date:  2020-10-24       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.